TBC1 domain family member 7Genealiases: MGCPH · PIG51 · TBC7
Q-omics provides the consensus-scored TBC1D7 profile across patient tissues and cancer cell-line models. TBC1D7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TBC1D7 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, TBC1D7 RNA expression shows 19,466 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where TBC1D7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D7 survival associations across molecular data types. TBC1D7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D7 RNA expression–survival associations across cancer types. High TBC1D7 expression shows unfavorable associations in UVM, BRCA, ACC, MESO, LIHC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TBC1D7 RNA expression.
This table summarizes TBC1D7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D7 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, COAD, LIHC and LUAD. The BLCA box plot shows higher TBC1D7 RNA expression in tumor versus normal tissue (log2 FC = +1.247, t-test p < 0.001).
This table shows molecular features associated with TBC1D7 in patient tissues and cancer cell lines. In patient samples, TBC1D7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SKIN.
